For the last century, drug development consisted of tiny-molecule treatments focused at mass audience. It worked for some patients while it didn’t for the rest. In some cases, we knew…
The post Top 6 issues facing the biotechnology industry appea…
This article was originally published by Christopher Southan, Peter Varkonyi, Kiran Boppana, Sarma A.R.P. Jagarlapudi, and Sorel Muresan at PLoS ONE 8(10): e77142. Abstract The statistics of drug development output and…
The post Tracking 20 Years…
Tracking 20 Years of Compound-to-Target Output from Literature and Patents Read Post »
By Larry Ramer, DrugPatentWatch writer Artificial intelligence, or AI, has advanced significantly in recent years and could significantly lower pharma companies’ R&D costs by enabling precision medicine and greatly reducing…
The post Can Arti…
Can Artificial Intelligence Help Drug Development? Read Post »
By: Pankaj Mondal, DrugPatentWatch Staff Writer When it comes to measuring the success of a new drug, the amount of time required to complete the entire approval process become a…
The post Accelerating Drug Approvals in the US appeared first on D…
The US pharmaceutical industry is heavily competitive, with nine out of the top ten pharmaceutical companies based in the US. In recent years though, the market has become even more competitive…
The post The Importance of Pharmaceutical Competito…
The Importance of Pharmaceutical Competitor Analysis Read Post »
SPINRAZA (nusinersen sodium) Biogen idec Patent: 6,166,197 Expiration: Dec 26, 2017 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected]…
The…
Drug Patent Expirations for the Week of December 24, 2017 Read Post »
Annual Drug Patent Expirations for KYNAMRO Kynamro is a drug marketed by Kastle Theraps Llc and is included in one NDA. There are three patents protecting this drug. This drug…
The post New patent expiration for Kastle Theraps drug KYNAMRO appeared fir…
New patent expiration for Kastle Theraps drug KYNAMRO Read Post »
Annual Drug Patent Expirations for SPINRAZA Spinraza is a drug marketed by Biogen Idec and is included in one NDA. It is available from one supplier. There are nine patents…
The post New patent expiration for Biogen Idec drug SPINRAZA appeared first on…
New patent expiration for Biogen Idec drug SPINRAZA Read Post »
Annual Drug Patent Expirations for NORDITROPIN+NORDIFLEX Norditropin Nordiflex is a drug marketed by Novo Nordisk Inc and is included in one NDA. It is available from two suppliers. There are…
The post New patent expiration for Novo Nordisk drug …
New patent expiration for Novo Nordisk drug NORDITROPIN NORDIFLEX Read Post »
Annual Drug Patent Expirations for NORDITROPIN+FLEXPRO Norditropin Flexpro is a drug marketed by Novo Nordisk Inc and is included in one NDA. It is available from two suppliers. There are…
The post New patent expiration for Novo Nordisk drug NORD…
New patent expiration for Novo Nordisk drug NORDITROPIN FLEXPRO Read Post »
Get new actionable insights and updates from BiotechBlog
